ReNeuron Group (AIM: RENE)

Currency in GBP

Last close As at 21/09/2023


−0.75 (−9.68%)

Market capitalisation


UK-based ReNeuron Group is focused on its stem cell-derived exosome drug delivery platform, CustomEx. The company is progressing the preclinical development of exosome-based therapeutics utilising its CustomEX technology.

Drug delivery remains a major challenge in both central nervous system (CNS) and cell and gene drug development, and we view these as key markets for ReNeuron to target with its exosome drug delivery platform. Additionally, ReNeuron’s diversification in exosome-producing stem cell lines and its ability to produce exosomes with enhanced natural tissue-targeting affinity, particularly neural stem cell lines to target CNS indications, may offer market differentiation against single cell line competitors.

Latest Insights

View More

Healthcare | Flash note

ReNeuron Group — A step forward on the Exosome delivery platform

Healthcare | Update

ReNeuron Group — Full steam ahead with CustomEx

Healthcare | Update

ReNeuron Group — Pushing on with CustomEx in H123



Equity Analyst

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Key Management

  • Ian Ross


  • John Hawkins


  • John Sinden

    Chief Scientific Officer

Balance Sheet

Forecast net cash (£m)


Forecast gearing ratio (%)


Share Price Performance

Price Performance
% 1M 3M 12M
Actual (28.2) (24.3) (74.1)
Relative (31.6) (24.7) (75.2)
52 week high/low 28.5p/5.8p


ReNeuron Group has generated in vivo data for CustomEX, marking a key step towards validating its proprietary stem cell-derived exosome platform. While the precise nature of the data is yet to be disclosed, we view the update as an encouraging sign and believe that it could improve traction for discussions for collaborations and partnerships, a key near-term goal for the company. ReNeuron now aims to broaden its capabilities by focussing on the functional delivery of specific therapeutics payloads, which we believe could include siRNA, mRNA, proteins, small molecules and genes, based on previous studies. Updates are expected in due course, potentially representing an important catalyst for investor attention, provided the data continue to be positive.

Y/E Mar Revenue (£m) EBITDA (£m) PBT (£m) EPS (fd) (p) P/E (x) P/CF (x)
2022A 0.4 N/A (11.1) (17.01) N/A N/A
2023A 0.5 N/A (6.7) (9.47) N/A N/A
2024E 0.9 N/A (7.1) (10.53) N/A N/A
2025E 12.3 N/A 3.9 5.72 1.2 1.0

Further insights



Stem cells

Analyst of the week

Soo Romanoff

Soo Romanoff

Managing Director - Head of Content, Healthcare

Read latest




ASCO 2023 key takeaways



Machine learning in drug development

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free